AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / LABORATORY ANALYTICAL INSTRUMENTS
Nautilus Biotechnolgy, Inc. Common Stock
XNAS · usd
SIC 3826 · LABORATORY ANALYTICAL INSTRUMENTS
FIGI BBG00W7G4MV9
3.24▲ 0.64 (24.62%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
—
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
2.60
Day's Range
2.57 – 3.26
52-Week Range
0.84 – 4.32
Volume
13.4M
Avg Volume
8.1M
Share Statistics
Shares Outstanding
Employees
130
Exchange
XNAS
Listed
2021-06-10
Share count as of July 24, 2026

Nautilus Biotechnolgy, Inc. Common Stock (NAUT) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Nautilus Biotechnolgy, Inc. Common Stock (NAUT)
What is Nautilus Biotechnolgy, Inc. Common Stock's Market Cap?
Nautilus Biotechnolgy, Inc. Common Stock's Market Cap is $412.3M, based on as-reported figures from SEC (XBRL) filings.
What is Nautilus Biotechnolgy, Inc. Common Stock's Enterprise Value?
Nautilus Biotechnolgy, Inc. Common Stock's Enterprise Value is $399.1M, based on as-reported figures from SEC (XBRL) filings.
What is Nautilus Biotechnolgy, Inc. Common Stock's Net Income (TTM)?
Nautilus Biotechnolgy, Inc. Common Stock's Net Income (TTM) is -$56.5M, based on as-reported figures from SEC (XBRL) filings.
What is Nautilus Biotechnolgy, Inc. Common Stock's Diluted EPS (TTM)?
Nautilus Biotechnolgy, Inc. Common Stock's Diluted EPS (TTM) is -0.44, based on as-reported figures from SEC (XBRL) filings.
What is Nautilus Biotechnolgy, Inc. Common Stock's Net Debt?
Nautilus Biotechnolgy, Inc. Common Stock's Net Debt is -$13.2M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · NAUTAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenue:
Total revenue———
Cost of revenue:
Total cost of revenue———
Operating expenses:
Research and development
Selling, general and administrative——
Total operating expenses
% of revenue8388.4%———
Other income (expense):
Interest income
Other expense
Total other income
Net loss
% of revenue-7615.3%———
Net loss per share attributable to common stockholders, basic (in dollars per share)
Net loss per share attributable to common stockholders, diluted (in dollars per share)